Adolat Mirzaeva
Family Practice · Houston, TXNPI 1447737556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 296 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novo Nordisk at 24.3% of the total. Among family practice clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$967
- AstraZeneca$874
- Boehringer Ingelheim$445
- GSK$344
- Lilly USA, LLC$340
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,394100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $1,312 |
| AbbVie | 62 | $967 |
| AstraZeneca | 46 | $874 |
| Boehringer Ingelheim | 30 | $445 |
| GSK | 21 | $344 |
| Lilly USA, LLC | 20 | $340 |
| Amgen | 9 | $194 |
| Bayer | 5 | $107 |
| Merck | 5 | $91 |
| Astellas Pharma US Inc | 4 | $88 |
| Exact Sciences | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Antares Pharma, Inc. | 3 | $45 |
| Gilead | 2 | $42 |
| Pfizer | 2 | $41 |
| Endo Pharmaceuticals Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Pulmonx Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$109
How this compares
$5,394 in reported general payments places this provider in the 95th percentile of 646 family practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 215 | $236,681 |
| MounjaroTirzepatide | 116 | $122,063 |
| OzempicSemaglutide | 66 | $91,537 |
| JanuviaSitagliptin Phosphate | 75 | $70,047 |
| RybelsusSemaglutide | 35 | $63,085 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $53,425 |
| Repatha SureclickEvolocumab | 35 | $31,485 |
| MyrbetriqMirabegron | 28 | $25,537 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 22 | $23,662 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $23,123 |
| FarxigaDapagliflozin Propanediol | 16 | $19,159 |
| ProliaDenosumab | 11 | $18,515 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $16,858 |
| EliquisApixaban | 15 | $16,724 |
| TrulicityDulaglutide | 16 | $14,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy Xr | $445 | $283,465258 claims |
| Novo NordiskOzempic, Rybelsus | $1,312 | $154,622101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $340 | $136,121132 claims |
| MerckJanuvia, Janumet Xr | $91 | $77,02387 claims |
| GSKTrelegy Ellipta | $344 | $53,42561 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $874 | $28,57129 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $25,53728 claims |
| PfizerEliquis, Premarin | $41 | $20,60931 claims |
| AmgenProlia | $194 | $18,51511 claims |
| AbbVieSynthroid | $967 | $2,07443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 646 family practice providers in Texas.
Other family practice in Houston
- Akhila ReddyHouston$7K
- Jillian PottkotterHouston$3K
- Ronke AloHouston$0
- Fareed KhanHouston$0
- Sree Latha RamphulHouston$0
- Dongni YangHouston$0
- Mark RobbinsSchertz$99K
- Lena BruceSanta Fe$8K
- William CalleyGarland$7K
- Leticia Arredondo CerdaSan Antonio$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.